Complicações Imediatas de 3.555 aplicações de agentes anti-TNFα

Complicações Imediatas de 3.555 aplicações de agentes anti-TNFα

OBJETIVO: Avaliar as complicações imediatas da aplicação de agentes anti-TNFα no Centro de Dispensação de Medicação deAlto Custo do HC-FMUSP. PACIENTES E MÉTODOS: Foram incluídos todos os pacientes que receberam agentes anti-TNFα entre agosto/2007 e março/2009.As complicações imediatas (até 1 hora a...

Full description

Bibliographic Details
Main Authors:	Júlio César Bertacini de Moraes, Nádia Emi Aikawa, Ana Cristina de Medeiros Ribeiro, Carla Gonçalves Schain Saad, Jozelio Freire de Carvalho, Rosa Maria Rodrigues Pereira, Clovis Artur Almeida Silva, Eloisa Bonfá
Format:	Article
Language:	English
Published:	Sociedade Brasileira de Reumatologia
Series:	Revista Brasileira de Reumatologia
Subjects:	anti-TNFα infliximabe etanercepte adalimumabe reações adversas agudas
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042010000200006&lng=en&tlng=en

Similar Items

Pregnancy Recommendations Solely Based on Preclinical Evidence Should Be Integrated with Real-World Evidence: A Disproportionality Analysis of Certolizumab and Other TNF-Alpha Inhibitors Used in Pregnant Patients with Psoriasis
by: Mario Gaio, et al.
Published: (2024-07-01)

New Treatment Alternatives in the Management of Non-‹nfectious ‹ntraocular ‹nflammations: Biologic Agents
by: Sinan Emre, et al.
Published: (2011-08-01)

Targeting psoriasis with new therapies
by: A.Prohić;H. Helppikangas;J. Muhović
Published: (2007-08-01)

HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE
by: A. S. Kolbin, et al.
Published: (2016-12-01)

Correlation of anti-TNF-a biological therapy with periodontal conditions and osteonecrosis in autoimmune patients: A systematic review
by: Rana Majdi Abunemer, et al.
Published: (2023-11-01)

Switching Among Biosimilars: A Review of Clinical Evidence
by: Eleonora Allocati, et al.
Published: (2022-08-01)

Pharmacovigilance in oncology: pattern of spontaneous notifications, incidence of adverse drug reactions and under-reporting
by: Marília Berlofa Visacri, et al.
Published: (2014-04-01)

Subvalorização das Artralgias: Papel do Enfermeiro na detecção precoce da Imunotoxicidade
by: Catarina Almeida, et al.
Published: (2021-06-01)

THE PROBLEMS OF THE SAFETY OF THERAPY WITH TUMOR NECROSIS FACTOR-а INHIBITORS
by: Dmitry Evgenyevich Karateyev
Published: (2009-09-01)

Access of high technology medicines in Russia
by: Liudmila Bezmelnitsyna, et al.
Published: (2015-12-01)

Systemic Psoriasis Treatment at an Early Age (Part II): Issues of Biological Therapy
by: L. S. Namazova-Baranova, et al.
Published: (2018-02-01)

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation
by: M Rodgers, et al.
Published: (2011-02-01)

Current views on the pharmacotherapy of psoriatic arthritis
by: G. G. Taradin, et al.
Published: (2016-01-01)

De-Escalation of Anti-Tumor Necrosis Factor Alpha Agents and Reduction in Adverse Effects: A Systematic Review
by: Marleen Bouhuys, et al.
Published: (2022-04-01)

The efficacy of anti–TNF-α agents in the treatment of juvenile idiopathic arthritis-associated uveitis in a pediatric cohort
by: Mai Nasser Abd ElMohsen, et al.
Published: (2023-01-01)

REAÇÕES ADVERSAS A ALIMENTOS E ACEITABILIDADE DO CARDÁPIO ESCOLAR POR CRIANÇAS ASSISTIDAS PELO PROGRAMA NACIONAL DE ALIMENTAÇÃO ESCOLAR– PNAE
by: Bruna Ferreira Ramos, et al.
Published: (2021-10-01)

COMPARAÇÃO ENTRE ESTRATÉGIAS DE FARMACOVIGILÂNCIA HOSPITALAR NOS PAÍSES DA AMÉRICA LATINA
by: Jaqueline Côrrea, et al.
Published: (2017-11-01)

ROLE OF TUMOR NECROSIS FACTOR ALPHA IN IMMUNE PATHOGENESIS OF DIFFERENT DISEASES AND ITS SIGNIFICANCE FOR EVOLVING ANTICYTOKINE THERAPY WITH MONOCLONAL ANTIBODIES
by: E. V. Voronina, et al.
Published: (2018-12-01)

Previsão de reações adversas dos anti-inflamatórios não esteroides por meio de modelação molecular
by: Fernando Banze C. Fernando, et al.
Published: (2023-07-01)

Fitovigilância: avaliação das interações e reações adversas de fitoterápicos no mercado
by: Ana Paula da Silva Roxo, et al.
Published: (2022-08-01)

Severe psoriatic arthritis in an HIV/AIDS patient treated with several TNF blockers switching: a case-based review
by: J. Carvalho, et al.
Published: (2022-01-01)

PE-055 Frequência de reações adversas em pacientes submetidos à dupla terapia antirretroviral em um hospital de referência de salvador – Brasil
by: Dulce Brás Impene Combo, et al.
Published: (2025-03-01)

Perfil das notificações de reações adversas a medicamentos antineoplásicos encaminhadas ao programa de farmacovigilância de um hospital universitário em Porto Alegre
by: Tatiana von Diemen, et al.
Published: (2023-12-01)

Food allergy: system immunologic and main food involved <br> Alergia alimentar: sistema imunológico e principais alimentos envolvidos
by: Patrícia Beltrão Lessa Constant, et al.
Published: (2008-10-01)

VigiMed: notificações de suspeitas de eventos adversos relacionados aos medicamentos no Rio Grande do Sul
by: Fabiane de Brito Malonn, et al.
Published: (2023-11-01)

Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study
by: Megna M, et al.
Published: (2022-07-01)

REAÇÕES ADVERSAS E ANAFILÁTICAS APÓS O USO DE PENICILINA BENZATINA EM GESTANTES COM SÍFILIS: REVISÃO INTEGRATIVA
by: Jaiza Sousa Penha, et al.
Published: (2020-06-01)

Análise da segurança do uso de imunossupressores por pacientes insuficientes renais
by: Fernanda Toaldo, et al.
Published: (2020-12-01)

Giant cell arteritis. Part III. New trends in its treatment (role of genetically engineered drugs)
by: Azamat Makhmudovich Satybaldyev
Published: (2013-03-01)

Incidencia de tuberculosis en pacientes que reciben fármacos anti-TNFα
by: Ana Gruss, et al.
Published: (2020-03-01)

Efeitos adversos da poliquimioterapia em pacientes com hanseníase: um levantamento de cinco anos em um Centro de Saúde da Universidade Federal de Uberlândia
by: Isabela Maria Bernades Goulart, et al.
Published: (2002-10-01)

Comparative efficacy of infliximab and adalimumab in patients with ankylosing spondylitis
by: Tatyana Valentinovna Mezenova, et al.
Published: (2012-04-01)

Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
by: Yoon Suk Jung, et al.
Published: (2021-01-01)

Eventos adversos a medicamentos entre idosos no Brasil antes e após o início da pandemia da COVID-19
by: Bruna Gomes de Souza, et al.
Published: (2022-08-01)

Sulfitos: importância na indústria alimentícia e seus possíveis malefícios à população
by: Diego Matos Favero, et al.
Published: (2015-02-01)

CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes andphenytoin adverse reactions correlation
by: Carlos Alexandre Twardowschy, et al.
Published: (2011-04-01)

Choice and switch of biologic drugs in juvenile idiopathic arthritis
by: Seher Şener, et al.
Published: (2023-12-01)

MANAGEMENT OF A PATIENT WITH SEVERE COURSE OF PSORIATIC ARTHRITIS
by: E. I. Alexeeva, et al.
Published: (2013-05-01)

Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real‐world finding
by: Zhe Yu, et al.
Published: (2024-02-01)

Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial
by: James Cheng-Chung Wei, et al.
Published: (2020-10-01)